-
Mashup Score: 24
Background and ObjectivesEpstein-Barr virus (EBV) has been strongly implicated in the pathogenesis of multiple sclerosis (MS). Despite this, there are no routinely used tests to measure cellular response to EBV. In this study, we analyzed the cellular …
Source: www.neurology.orgCategories: General Medicine News, NeurologyTweet
-
Mashup Score: 61Multiple Sclerosis, Rituximab, Hypogammaglobulinemia, and Risk of Infections | Neurology Neuroimmunology & Neuroinflammation - 1 month(s) ago
Background and ObjectivesB-cell–depleting therapies increase the risk of infections and hypogammaglobulinemia. These relationships are poorly understood. The objectives of these analyses were to estimate how much of this rituximab-associated infection …
Source: www.neurology.orgCategories: General Medicine News, NeurologyTweet
-
Mashup Score: 59Myeloid cell replacement is neuroprotective in chronic experimental autoimmune encephalomyelitis - 1 month(s) ago
Nature Neuroscience – Hematopoietic cell transplantation (HCT) may be a promising therapy for treatment-refractory multiple sclerosis (MS). Mader et al. Describe beneficial effects of autologous…
Source: www.nature.comCategories: General Medicine News, NeurologyTweet
-
Mashup Score: 11Adverse Events Associated with Use of Disease-Modifying Drugs in MS - 2 month(s) ago
Numerous randomized controlled trials have studied the efficacy of disease-modifying drugs (DMDs) in patients with multiple sclerosis (MS). However,
Source: www.jwatch.orgCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 28Adverse Events Associated With Disease-Modifying Drugs for Multiple Sclerosis: A Multiregional Population-Based Study: Neurology: Vol 102, No 3 - 4 month(s) ago
Background and ObjectivesIt is not possible to fully establish the safety of a disease-modifying drug (DMD) for multiple sclerosis (MS) from randomized controlled trials as only very common adverse events occurring over the short-term can be captured, and …
Source: www.neurology.orgCategories: General Medicine News, NeurologyTweet-
Class III evidence that for patients with #MS, while disease-modifying drug (DMD) exposure reduces the risk of infection-related hospitalizations, there are increased risks of infection-related physician visits and incident adverse events for select DMDs: https://t.co/qV9wjr5FiV https://t.co/gLBxc2pkMa
-
-
Mashup Score: 0
Multiple sclerosis (MS) is a major diagnosis that can upend your life in many ways, but getting diagnosed early can slow the progression of this disability.
Source: www.henryford.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 11
Background and ObjectivesThe factors that drive progression in multiple sclerosis (MS) remain obscure. Identification of key properties of meningeal inflammation will contribute to a better understanding of the mechanisms of progression and how to prevent …
Source: www.neurology.orgCategories: General Medicine News, NeurologyTweet
-
Mashup Score: 33Association Between Diseases and Symptoms Diagnosed in Primary Care and the Subsequent Specific Risk of Multiple Sclerosis | Neurology - 5 month(s) ago
Background and ObjectivesPrevious studies have reported a possible prodrome in multiple sclerosis (MS) defined by nonspecific symptoms including mood disorder or genitourinary symptoms and increased health care use detected several years before diagnosis. …
Source: www.neurology.orgCategories: General Medicine News, NeurologyTweet-
In this study on 2 large independent primary care databases, 5 conditions (depression, sexual dysfunction, constipation, cystitis, & urinary tract infections of unspecified site) were significantly associated with a subsequent diagnosis of #MS. Learn more: https://t.co/n8l7HuQ65J https://t.co/EjP8J1gmLD
-
-
Mashup Score: 1Are We Ready for Biosimilars in Multiple Sclerosis? Experts Discuss Lessons From Other Immune-Mediated Diseases - 7 month(s) ago
What is the clinical use of biosimilars and how to best communicate with patients to avoid the nocebo effect?
Source: www.medscape.orgCategories: Latest Headlines, NeurologyTweet
-
Mashup Score: 0
Did you know what the inherent variability of all biologics and what degree of variation are acceptable by regulatory bodies?
Source: www.medscape.orgCategories: Latest Headlines, NeurologyTweet
In this study, @hugh_kearney and colleagues developed a novel, easily scalable, and translatable test of cellular response to the EBV latent antigen, EBNA-1. They report a differential effect of a range of DMTs in #MS on the cellular response to EBNA-1: https://t.co/z7aEgYDmYO https://t.co/3ScX4R0GGF